Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN versus PIPERACILLIN.
Head-to-head clinical analysis: AMPICILLIN versus PIPERACILLIN.
Ampicillin vs PIPERACILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin is a penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
250-500 mg orally every 6 hours; 1-2 g IV/IM every 4-6 hours.
3.375 g IV every 6 hours (piperacillin-tazobactam); for piperacillin alone, 3 g IV every 6 hours.
None Documented
None Documented
Terminal elimination half-life: 1-1.8 hours in adults with normal renal function; prolonged to 7-20 hours in end-stage renal disease (CrCl <10 mL/min).
Clinical Note
moderateAmpicillin + Acemetacin
"Ampicillin may decrease the excretion rate of Acemetacin which could result in a higher serum level."
Clinical Note
moderateAmpicillin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Ampicillin."
Clinical Note
moderateBacampicillin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Bacampicillin."
Clinical Note
moderatePivampicillin + Probenecid
0.6-1.2 hours in adults with normal renal function; prolonged to 2-6 hours in renal impairment (CrCl <20 mL/min); requires dose adjustment in renal failure
Renal: 90% unchanged via glomerular filtration and tubular secretion; biliary: 10% (small amount).
Renal: approximately 70-90% unchanged via glomerular filtration and tubular secretion; biliary: 10-20% excreted unchanged in bile; fecal: minor (<5%)
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic
"The serum concentration of Probenecid can be increased when it is combined with Pivampicillin."